S
ALNY icon

Sachetta’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sachetta’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33
Closed -$10.9K – 1035
2026
Q1 		$10.9K Hold
33
– – 0.01% 426
2025
Q4 		$13.1K Sell
33
-40
-55% -$17.7K 0.01% 344
2025
Q3 		$33.3K Hold
73
– – 0.01% 307
2025
Q2 		$23.8K Buy
73
+7
+11% +$1.94K 0.01% 333
2025
Q1 		$17.8K Sell
66
-2
-3% -$514 0.01% 357
2024
Q4 		$16K Sell
68
-3
-4% -$789 0.01% 388
2024
Q3 		$19.5K Buy
71
+41
+137% +$10.7K 0.01% 372
2024
Q2 		$7.01K Buy
30
+11
+58% +$1.74K ﹤0.01% 515
2024
Q1 		$3.64K Hold
19
– – ﹤0.01% 580
2023
Q4 		$3.64K Buy
+19
New +$3.24K ﹤0.01% 580

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sachetta's ALNY Position: Q2 2026 in Review

Sachetta sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 33 shares — an estimated $10.9K sold.

Sachetta first reported a position in ALNY in Q4 2023 and held it in 10 quarters. The position peaked at $33.3K in Q3 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Sachetta reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Sachetta sold 33 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $10.9K.
  • Sachetta first reported a position in Alnylam Pharmaceuticals in Q4 2023 and held it in 10 quarters.
  • Sachetta's Alnylam Pharmaceuticals position peaked at $33.3K in Q3 2025.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Sachetta's 13F filing for Q2 2026, filed 15 Jul 2026.